Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions
Open Access
- 25 September 2024
- journal article
- review article
- Published by Elsevier in European Urology Oncology
- Vol. 8 (2) , 494-509
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected MelanomaJAMA Network Open, 2023
- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trialsAnnals of Oncology, 2023
- How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?World Journal of Urology, 2022
- LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trialAnnals of Oncology, 2022
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaCancer, 2022
- Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell CarcinomaEuropean Urology Oncology, 2021
- Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyEuropean Journal of Cancer, 2021
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCancer Cell, 2020
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx RenalCell, 2018